Advertisement

Obesity Surgery

, Volume 28, Issue 7, pp 2113–2116 | Cite as

Liraglutide Effects on Upper Gastrointestinal Investigations: Implications Prior to Bariatric Surgery

  • Renuca Modi
  • Peter Rye
  • Sarah Cawsey
  • Daniel W. Birch
  • Arya M. Sharma
Brief Communication

Abstract

Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue that is approved for long-term obesity management in North America. While bariatric surgery remains the gold standard for weight loss, an increasing number of patients are on liraglutide in the setting of ongoing workup for bariatric surgery. The presence of gastrointestinal symptoms prior to bariatric surgery may prompt testing for dysmotility, which affects surgical decision making. Here we report six cases where treatment with liraglutide was associated with reversible reduction in gastric and esophageal motility in screening for bariatric surgery. While liraglutide is known to delay gastric emptying, there are minimal reports of how this medication affects gastrointestinal investigations used in this context. The implications of these abnormal screening investigations on candidacy for bariatric surgery are discussed.

Keywords

Liraglutide Bariatric surgery Roux-en Y Sleeve gastrectomy Gastroparesis Esophageal dysmotility 

Notes

Compliance with Ethical Standards

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent was obtained from all individual participants included in the study.

Conflict of Interest

Dr. Modi has received speaker fees for educational events and honoraria for the development of educational materials from NovoNordisk Canada and Shire Pharma Canada. She has also received speaker fees from Valeant Canada and serves on the advisory board. Dr. Cawsey has received speaker fees and consulting fees from NovoNordisk Canada. Dr. Sharma has received speaker fees and consulting fees from NovoNordisk Canada and Merck.  He also serves on the advisory board for Valeant Canada.

References

  1. 1.
    Shaefer CF, Kushner P, Aguilar R. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015;127(8):818–26.CrossRefPubMedGoogle Scholar
  2. 2.
    Novo Nordisk Canada Inc. Saxenda® Product Monograph. http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/Saxenda_PM_English.pdf. Published 2017 July 12. Accessed 10 December 2017.
  3. 3.
    Naik RD, Choksi YA, Vaezi MF. Consequences of bariatric surgery on oesophageal function in health and disease. Nat Rev Gastroenterol Hepatol. 2016;13(2):111–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Seok JW. How to interpret gastric emptying scintigraphy. J Neurogastroenterol Motil. 2011;17(2):189–91.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Patel A, Gyawali CP. How to optimally apply impedance in the evaluation of esophageal dysmotility. Curr Gastroenterol Rep. 2016;18:60.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Assef MS, Melo TT, Araki O, et al. Evaluation of upper gastrointestinal endoscopy in patients undergoing bariatric surgery. Arq Bras Cir Dig. 2015;28(Suppl 1):39–42.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Piche T, Des varannes SB, Sacher-huvelin S, et al. Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease. Gastroenterology. 2003;124(4):894–902.CrossRefPubMedGoogle Scholar
  8. 8.
    Van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obesity (2005). 2014;38(6):784–93.CrossRefGoogle Scholar
  9. 9.
    Horowitz M, Flint A, Jones KL, et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012;97(2):258–66.CrossRefPubMedGoogle Scholar
  10. 10.
    Nakatani Y, Maeda M, Matsumura M, et al. Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy. Diabetes Metab. 2017; [Epub ahead of print];43:430–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Khemani D, Eckert D, O’Neil J, et al. Effect of liraglutide on gastric emptying at 5 and 16 weeks: a single-center, randomized, placebo-controlled trial in 32 patients. Gastroenterology. 2017;152(5):S83.CrossRefGoogle Scholar
  12. 12.
    Meier JJ, Rosenstock J, Hincelin-Mery A, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care. 2015;38(7):1263–73.CrossRefPubMedGoogle Scholar
  13. 13.
    Nagai Y, Hashimoto E, Oikawa R, et al. Differing effects of liraglutide on gastric emptying in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2014;16(6):573–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Sun Z, Rodriguez J, Mcmichael J, et al. Surgical treatment of medically refractory gastroparesis in the morbidly obese. Surg Endosc. 2015;29(9):2683–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Papasavas PK, Ng JS, Stone AM, et al. Gastric bypass surgery as treatment of recalcitrant gastroparesis. Surg Obes Relat Dis. 2014;10(5):795–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Renuca Modi
    • 1
    • 2
  • Peter Rye
    • 3
  • Sarah Cawsey
    • 2
    • 4
  • Daniel W. Birch
    • 5
  • Arya M. Sharma
    • 2
    • 4
  1. 1.Department of Family MedicineUniversity of AlbertaEdmontonCanada
  2. 2.Edmonton Adult Bariatric Specialty ClinicRoyal Alexandra Hospital, EdmontonEdmontonCanada
  3. 3.Richmond Road Diagnostic Treatment CentreUniversity of CalgaryCalgaryCanada
  4. 4.Division of Endocrinology and Metabolism, Department of MedicineUniversity of AlbertaEdmontonCanada
  5. 5.Division of General Surgery, Department of SurgeryUniversity of AlbertaEdmontonCanada

Personalised recommendations